Alfasigma agrees to acquire Nordic Pharma to expand European specialty care business
- nuaxia
- 4일 전
- 2분 분량
The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.
Alfasigma has entered a share purchase agreement with SEVER Life Sciences to acquire 100% of Nordic Group B.V. (Nordic Pharma) and its subsidiaries, with financial terms not disclosed.
The transaction would add Nordic Pharma’s rheumatoid arthritis, women’s health, critical care and ophthalmology portfolio while significantly expanding Alfasigma’s specialty-care commercial infrastructure across Europe and selected international markets.
Field | Content |
Alert Type | Deal |
Companies | Alfasigma; Nordic Group B.V. (Nordic Pharma); SEVER Life Sciences B.V. |
Deal Type | Acquisition |
Asset or Company | 100% of Nordic Group B.V. and its subsidiaries |
Therapy Area(s) | Rheumatology; Women’s health; Critical care; Ophthalmology |
Deal Value | Financial terms have not been disclosed. Nordic Pharma generated approximately €190 million in revenue in 2025, but this represents company revenue rather than transaction consideration. (Via Ritzau) |
Geography | Europe; Canada; Japan |
What Happened | On 11 August 2026, Alfasigma announced that it had entered into a share purchase agreement with SEVER Life Sciences to acquire 100% of Nordic Group B.V. and its subsidiaries. The transaction would add Nordic Pharma’s specialty pharmaceutical portfolio, including its Nordimet (methotrexate) rheumatoid arthritis franchise, as well as businesses in women’s health, critical care and ophthalmology. Nordic Pharma has direct operations in 18 European countries and commercial platforms in Canada and Japan, with approximately 265 employees. The acquisition remains subject to customary closing conditions, including required regulatory clearances. (Via Ritzau) |
Why It Matters | Nordic Pharma adds an established specialty-care portfolio and commercial infrastructure that complements Alfasigma’s existing international expansion strategy. In rheumatology, Nordimet would sit alongside Alfasigma’s existing Jyseleca (filgotinib) franchise, while Nordic Pharma’s direct operations broaden the geographic infrastructure available to commercialise specialty and rare-disease medicines. (Via Ritzau) |
Supporting Context | Alfasigma has been expanding its specialty and rare-disease portfolio through acquisitions and licensing, with particular focus on gastroenterology and immunology. Recent moves include its acquisition of Jyseleca in inflammatory diseases and a licensing agreement with GSK for linerixibat in cholestatic pruritus associated with primary biliary cholangitis. (Via Ritzau) |
Strategic Rationale | Alfasigma gains Nordic Pharma’s rheumatoid arthritis franchise, additional specialty-care portfolios, 265 employees and direct commercial operations across multiple European markets, Canada and Japan. The transaction therefore combines portfolio expansion with a material increase in Alfasigma’s international commercial reach. (Via Ritzau) |
Potential Impact | If completed, the acquisition could provide Alfasigma with a broader platform for launching and commercialising specialty and rare-disease medicines internationally, particularly across Europe. The eventual impact will depend on successful transaction completion and integration of Nordic Pharma’s portfolio and operations. |
Key Takeaway | The Nordic Pharma acquisition would add approximately €190 million in annual revenue while giving Alfasigma a broader specialty-care portfolio and substantially larger direct commercial footprint across Europe and selected international markets. |
What to Watch | Required regulatory clearances, completion of the acquisition and Alfasigma’s subsequent integration of Nordic Pharma’s portfolio, employees and international commercial operations. (Via Ritzau) |
Primary Source | |
Relevant Date | 11 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글